Go to content
Koninklijke Philips N.V.

Koninklijke Philips N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 21 jan 2008 - 07:05
Statutaire naam Koninklijke Philips N.V.
Titel Philips delivers on its targets: solid Q4 with 8% comparable sales growth and EBITA of EUR 865 million.
Bericht January 21, 2008 PHILIPS DELIVERS ON ITS TARGETS: SOLID Q4 WITH 8% COMPARABLE SALES GROWTH AND EBITA OF EUR 865 MILLION. Full-year 2007 comparable sales up 5%, delivering an EBITA margin of 7.7%. • Comparable sales increased by 8% to EUR 8,365 million, driven by strong growth at Lighting and the consumer businesses, particularly in emerging markets, where sales growth was 18%. • EBITA as a percentage of sales grew by 1.1 percentage points compared to Q4 2006 to reach 10.3%, or EUR 865 million. • Net income amounted to EUR 1,393 million; the increase in earnings was boosted by EUR 1,087 million in gains on the sale of stakes in LG.Philips LCD and TSMC. • The announced acquisitions of Genlyte and Respironics strengthen Philips leadership positions in Lighting and Home Healthcare. • Following an amendment to Dutch tax legislation, the Company announced a further EUR 5 billion (tax-free) share repurchase plan. • It is proposed to increase the dividend for 2007 by 17% to EUR 0.70 per share. • Our Q4 financial performance – and the other progressive steps taken during the quarter – puts Philips well on track to achieve its Vision 2010 goals. Gerard Kleisterlee, President and CEO of Royal Philips Electronics: "I am pleased to report that in the fourth quarter Philips once again delivered on its targets. Q4’s 8% comparable sales growth and 10.3% EBITA margin brought our full-year numbers to 5% for growth and 7.7% for EBITA, meeting, respectively exceeding, our targets for the year thereby sustaining our track record of "saying what we do and doing what we say". Operationally, we are well-positioned to achieve our Vision 2010 targets. Strategically, the acquisitions of Genlyte and Respironics, together with other important acquisitions of 2007 such as Partners in Lighting and Color Kinetics, will strengthen our portfolio by further building up global leadership positions in promising markets such as LED lighting and home healthcare. Financially, our capital realloc